First-in-class targets in validated pathways and the right patient subset
Our approach to oncology drug development combines deep understanding of target biology and antibody mechanism of action with rigorous patient selection. This allows us to precisely target likely responders and – enabled by extensive patient biomarker data analysis in the clinic – develop rational combination therapies based on the specific immunomodulatory mechanisms of our drug candidates.
MSC-1 is a first-in-class antibody that targets leukemia inhibitory factor (LIF), a pleiotropic cytokine that is overexpressed in most solid tumor types. LIF is hypothesized to drive a broad program of immunosuppression in the tumor microenvironment, and supports self-renewal in tumor-initiating cells. MSC-1 is expected to begin clinical trials in several cancerous tumor types in late-2017, with multiple study sites planned in Europe and North America.